Lemborexant (Dayvigo) (Lemborexant) for Personal Injury

Drug Class: Dual Orexin Receptor Antagonist (DORA) — Sleep

Common Uses

  • Sleep onset difficulty after personal injury
  • Sleep maintenance difficulties (waking during the night)
  • Insomnia secondary to injury-related pain
  • Chronic insomnia secondary to PTSD following accidents

How It Helps in Personal Injury Cases

Lemborexant (Dayvigo) was the first dual orexin receptor antagonist (DORA) approved in the United States (December 2019). Like daridorexant (Quviviq), it works by blocking orexin rather than sedating the brain broadly. The 10mg dose is particularly effective for sleep maintenance — the pattern of waking repeatedly through the night due to positional pain, which is very common in PI patients with back, shoulder, and cervical injuries.

Lemborexant blocks OX1R and OX2R orexin receptors, reducing the wake-promoting orexin signal and allowing the brain's natural sleep mechanisms to produce both sleep onset and sustained sleep maintenance. Its pharmacokinetic profile — with a half-life that allows strong sleep maintenance effects without excessive morning carryover — makes it well-suited for patients who wake repeatedly due to pain during the night.

Lemborexant (Dayvigo) for Sleep Disruption After a Personal Injury

Lemborexant, sold as Dayvigo, was the first dual orexin receptor antagonist approved in the United States (December 2019). It blocks orexin — the wake-promoting neuropeptide — rather than broadly sedating the brain, providing improved sleep architecture without the next-day impairment of older sleep medications.

Particularly Effective for Sleep Maintenance

Lemborexant is especially effective for patients who wake repeatedly during the night — a pattern very common in PI patients whose positional pain (back, shoulder, neck) disrupts sleep at each sleep-wake transition. The 10mg dose provides strong sleep maintenance effects throughout the night.

Dosing

  • 5mg immediately before bed — sleep onset + mild maintenance
  • 10mg immediately before bed — stronger sleep maintenance for frequent nighttime waking

Orexin Mechanism in Injury Context

Physical pain signals and hyperarousal from PTSD or anxiety keep orexin signaling elevated in PI patients, actively preventing sleep even during periods of exhaustion. Lemborexant blocks both orexin receptor subtypes (OX1R and OX2R), removing this wake-promoting drive and allowing natural sleep mechanisms to function.

Documentation Value in PI Cases

Sleep disruption is a documentable functional impairment of personal injury. A Dayvigo prescription reflects:

  • Physician determination that sleep disruption requires pharmacological intervention
  • Clinical selection of a modern, evidence-based sleep medication
  • Ongoing sleep-related injury management alongside physical treatment

The 10mg dose specifically documents significant sleep maintenance difficulty — the kind of repeated nighttime waking that is characteristic of pain-disrupted sleep.

Accessing Lemborexant Through LienScripts

Lemborexant (Dayvigo) is brand-name only. LienScripts provides pharmacy lien coverage at $0 upfront cost for qualified personal injury patients.

Dosage Forms

  • Tablet 5mg (starting dose — sleep onset and mild maintenance)
  • Tablet 10mg (stronger sleep maintenance — for patients who wake during the night)
  • Taken immediately before bedtime

Common Side Effects

  • Somnolence next day (dose-dependent; 10mg more than 5mg)
  • Headache
  • Fatigue (uncommon)
  • Dizziness (uncommon)
  • Abnormal dreams (uncommon)

Frequently Asked Questions

Is Dayvigo better for falling asleep or staying asleep?

Lemborexant is effective for both sleep onset and sleep maintenance. The 5mg dose primarily addresses sleep onset difficulty. The 10mg dose provides stronger sleep maintenance — better for patients who fall asleep but wake repeatedly during the night, which is a common pattern when injury pain causes positional waking.

How does lemborexant compare to daridorexant (Quviviq)?

Both are dual orexin receptor antagonists with similar mechanisms. Daridorexant (Quviviq) was approved in 2022, three years after lemborexant (2019). Some clinicians prefer one over the other based on pharmacokinetic differences — lemborexant's longer half-life provides robust sleep maintenance but may produce slightly more next-day somnolence at the 10mg dose compared to daridorexant.

Is Dayvigo a controlled substance?

Lemborexant is Schedule IV. Despite the scheduling, its mechanism (orexin blockade rather than GABA potentiation) provides a fundamentally different and safer profile than benzodiazepines or Z-drugs that share the Schedule IV classification.

Is there a generic for Dayvigo?

No. Lemborexant is available only as Dayvigo with no generic alternative.